Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Polaryx Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Polaryx Therapeutics, Inc.’s stock price such as:

• Polaryx Therapeutics, Inc.’s current stock price and volume
• Why Polaryx Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for PLYX from analysts
• PLYX’s stock price momentum as measured by its relative strength

About Polaryx Therapeutics, Inc. (PLYX)

Before we jump into Polaryx Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.

Want to learn more about Polaryx Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Polaryx Therapeutics, Inc..

Polaryx Therapeutics, Inc.’s Stock Price as of Market Close

As of May 21, 2026, 4:00 PM, CST, Polaryx Therapeutics, Inc.’s stock price was $3.940.

Polaryx Therapeutics, Inc. is up 16.57% from its previous closing price of $3.380.

During the last market session, Polaryx Therapeutics, Inc.’s stock traded between $3.300 and $4.030. Currently, there are approximately 47.22 million shares outstanding for Polaryx Therapeutics, Inc..

Polaryx Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Polaryx Therapeutics, Inc. Stock Price History

Polaryx Therapeutics, Inc.’s (PLYX) price is currently down 24.95% so far this month.

During the month of May, Polaryx Therapeutics, Inc.’s stock price has reached a high of $5.490 and a low of $2.570.

Over the last year, Polaryx Therapeutics, Inc. has hit prices as high as $48.910 and as low as $2.201.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Polaryx Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 20, 2026, there were analysts who downgraded Polaryx Therapeutics, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Polaryx Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Polaryx Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Polaryx Therapeutics, Inc. (PLYX) by visiting AAII Stock Evaluator.

Relative Price Strength of Polaryx Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 20, 2026, Polaryx Therapeutics, Inc. has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how Polaryx Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Polaryx Therapeutics, Inc. Stock Price: Bottom Line

As of May 21, 2026, Polaryx Therapeutics, Inc.’s stock price is $3.940, which is up 16.57% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Polaryx Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.